Evidence map›Paper›PMID 27075010›Full record

ArticleLupus2016

Urinary high-mobility group box-1 associates specifically with lupus nephritis class V.

N R Jog, I Blanco, I Lee, C Putterman, R Caricchio

Open access · greenAbstract read
In one paragraph

Article in Lupus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Urinary and serum levels of high mobility group box 1.Practical laboratory medicine · 2023
    Article
  5. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease.International journal of biological sciences · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Common innate pathways to autoimmune disease.Clinical immunology (Orlando, Fla.) · 2020
    Review
  10. Review
  11. Review
  12. Article
  13. Biomarkers in connective tissue diseases.The Journal of allergy and clinical immunology · 2017
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

N R JogRheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
I BlancoDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA.
I LeeNephrology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
C PuttermanDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA.
R CaricchioRheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA roc@temple.edu.
Temple University · USAlbert Einstein College of Medicine · US

Funding

Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
The role of cell death in Lupus NephritisR01AR061569 · NIAMS · TEMPLE UNIV OF THE COMMONWEALTH · PI CARICCHIO, ROBERTO · 2012 to 2016
$2.3M
Clinical and Translational Science Award-K12KL2RR025749 · NCRR · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SHAMOON, HARRY · 2008 to 2011
$991k
NCATS NIH HHS UL1 TR001073NCRR NIH HHS KL2 RR025749NIAMS NIH HHS R01 AR061569
6 · The paper itself

Abstract

introductionHigh-mobility group box 1 protein (HMGB-1) has been implicated in the pathogenesis of lupus nephritis (LN). There is increased HMGB-1 expression in the kidneys and increased levels are observed in serum and urine of patients with LN. This study was performed to determine whether the increased urinary HMGB-1 was specific for active lupus or secondary to renal damage.

methodsUrine from 61 lupus patients (32 had active LN and 29 had systemic lupus erythematosus (SLE) with no evidence of LN) and 14 control proteinuric patients (all with hypertension and eight also with diabetes) were included in this study. HMGB-1 was detected by Western blot. Urine protein was normalized to urine creatinine to account for volume of the specimen.

resultsMedian normalized urine HMGB-1 levels were significantly elevated in LN patients compared to lupus patients without kidney disease (53.81 vs 9.46, p < 0.001). A difference in median levels was seen between LN classes, with a significant difference between proliferative and membranous disease (33.4 vs 138.8, p = 0.003). Urine protein to urine creatinine ratio (P/C) correlated with urinary HMGB-1 (r = 0.52, p < 0.001), but across the classes this was true only for membranous disease (r = 0.71, p = 0.022, proliferative, p = 0.63; mixed, p = 0.34).

conclusionsHMGB-1 is elevated in the urine of patients with active LN. Levels are associated with LN class, and higher levels of urinary HMGB-1 are seen in patients with class V when compared to both proliferative and mixed classes. Therefore, urinary HMGB-1 may be suggestive of membranous LN and warrants further evaluation in a large lupus cohort.

Indexed as

AdultAgedBiomarkersCreatinineFemaleGlomerulonephritis, MembranousHMGB1 ProteinHumansKidneyKidney Function TestsLupus NephritisMaleMiddle AgedSeverity of Illness IndexUrinalysisBiomarkersCreatinineHMGB1 ProteinHMGB-1lupus nephritismembranous nephritis

Identifiers

PMID27075010
PMCPMC5061582
OpenAlexW2338273860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.